Proteasome inhibitors, used to treat multiple myeloma patients evoke ER-stress and apoptosis by blocking the ER-associated degradation of misfolded proteins (ERAD), however, the role of eIF2α phosphorylation in leukemic cells under conditions of proteasome inhibitor-mediated ER stress is currently unclear. This evidence concerns the gene EIF2A and plasma cell myeloma.